Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Diverticulitis Drugs Market size is set to expand at significant growth rate during the forecast period i.e., between 2025-2037.
This growth can be attributed to the growing prevalence of obesity, rising old age population, and the inclination of youth towards an unhealthy lifestyle. Moreover, eating excessive red meat, and lack of fiber in diet can also lead to diverticulitis. According to a report by the World Health Organization, more than 2 billion people in the world do not have access to a balanced diet. In another report of the WHO, it is stated that around 1.9 billion adults were overweight and 650 million were obese, in the year 2016. In fact, at present, there are more overweight individuals than underweight, globally. This is estimated to elevate the prevalence of diverticulitis, which in turn, is estimated to boost the market growth. Additionally, factors such as government initiatives and support to treat the disease, rising demand for advanced treatment options, and growing market players offering newer products, are anticipated to drive the growth of the market over the coming years.
Diverticulitis Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Trend of Sedentary Lifestyle and Unhealthy Diet
- Increasing Global Geriatric Population
Restraints
- Lack of Awareness among People Regarding the Disease
- Stringent Regulations of the Government Regarding the Approval of Medicines
Diverticulitis Drugs Market: Key Insights
Diverticulitis Drugs Segmentation
The market is segmented by end-user into specialty clinics, hospitals, research centers, and others. Among these, the hospitals segment is anticipated to hold the largest market share over the forecast period on the back of symptoms and complications associated with the disease. Its symptoms include cramps on the left side of the abdomen which goes away after passing gas or stool, abdominal pain, fever, diarrhea, bloating, bleeding from rectum, bright red blood in stool, and others, which often need immediate attention from medical staff.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDiverticulitis Drugs Industry - Regional Synopsis
On the basis of regional analysis, the diverticulitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region.
North America industry is predicted to dominate majority revenue share by 2037, on account of rising obese population, and availability of advanced treatment options. Additionally, the growing cases of various gastrointestinal diseases, including diverticulitis, is estimated to boost the market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in the United States, about 58% of the individuals above 60 years of age have diverticulosis and about 5% of people with diverticulosis tends to develop diverticulitis. According to another report by the NIDDK, around 200,000 individuals are hospitalized for diverticulitis each year in the United States.
The market in the Asia Pacific is anticipated to grow at the highest CAGR over the forecast period owing to the growing number of patients, rising awareness among the individuals regarding health, availability of new treatment methods, improvement in the standard of living, and rapidly improving health care infrastructure.
Companies Dominating the Diverticulitis Drugs Landscape
- Emmaus Life Sciences, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Synergy Pharma
- Abbott Laboratories
- GlaxoSmithKline plc
- Ardelyx, Inc.
- Gilead Sciences, Inc.
- Trumac Healthcare
- Pfizer Inc.
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
In the News
- January 29, 2020: Emmaus Life Sciences, Inc. has announced the preliminary results observed in the first patient in the company’s phase 1 study of diverticulosis treatment. The results were satisfactory and the company intends to continue the research and development process for novel drugs to treat diverticulitis
- May 28, 2020: Hikma Pharmaceuticals PLC launched Dicyclomine Hydrochloride Oral Solution for the treatment of various inflammatory bowel diseases, including diverticulosis.
Author Credits: Radhika Pawar
- Report ID: 3054
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
